Home› Library› Protocol› Cjc 1295 ipamorelin
CJC-1295 / Ipamorelin reconstitution protocol
Reconstitution for blended CJC-1295 + Ipamorelin vials. Why the combination is shipped together, single-vial handling, and references for the underlying GHRH/GHRP pharmacology.
RECONSTITUTION & RESEARCH PROTOCOLS
Preclinical literature onlyResearch protocol intensities, summarized from published literature. The math is computed for the vial size you pick. Not a dosing recommendation.
CJC-1295 has limited Phase 1 PK data (Teichman et al., JCEM 2006). The combination with Ipamorelin is supplier-derived; no human RCT evidence for the blend.
Reference research protocols from published peer-reviewed studies. Each card cites its source. This calculator is not a dosing recommendation. For research use only. Selection of any specific protocol is the responsibility of the qualified investigator under appropriate institutional oversight.
This protocol describes the reconstitution and storage of lyophilized CJC-1295 + Ipamorelin blended vials in standard research workflows. The two peptides are co-formulated because they target complementary growth-hormone-axis receptors and are typically studied together. Values below are derived from published handling literature; experimental design parameters are the responsibility of the qualified investigator.
At a glance
| Parameter | Value |
|---|---|
| Recommended diluent | Bacteriostatic Water (USP, 0.9% benzyl alcohol) |
| Recommended volume (10 mg vial, 5 mg CJC-1295 + 5 mg Ipamorelin) | 2.0 mL |
| Final concentration | 2.5 mg/mL CJC-1295 + 2.5 mg/mL Ipamorelin (5 mg/mL combined peptide) |
| Stability — lyophilized | ≥24 months at -20 °C, light-protected, sealed |
| Stability — reconstituted | 30 days at 2–8 °C in original vial |
Procedure
- Equilibrate. Allow vial to reach room temperature.
- Sterile prep. Wipe stopper with isopropyl. Use sterile syringe + needle.
- Inject diluent slowly along the inner wall. Both peptides dissolve readily.
- Swirl gently. Do not shake. Cake dissolves within 30–60 seconds.
- Verify. Solution should be clear and colorless.
Why the two peptides are blended
CJC-1295 (without DAC) is a synthetic analog of growth-hormone-releasing hormone (GHRH) — it stimulates the pituitary to release endogenous growth hormone. Ipamorelin is a selective growth-hormone secretagogue (GHRP) that activates the ghrelin receptor (GHS-R1a), also stimulating GH release through a complementary pathway. The combination provides a synergistic signal to the pituitary in research models: the two peptides activate different receptors that converge on the same downstream effect, producing a larger and more physiologically-shaped GH pulse than either alone.
Importantly, Ipamorelin is more selective than older GHRPs (like GHRP-2 or GHRP-6) — it does not meaningfully elevate cortisol or prolactin in published studies, which is why it became the preferred GHRP for research combinations.
Storage
Reconstituted blend is stable for approximately 30 days at 2–8 °C in the original vial. For longer storage, aliquot into sterile single-use tubes and freeze at -20 °C or colder. Avoid freeze-thaw on reconstituted material. Lyophilized stability is ≥24 months at -20 °C light-protected.
Notes
This protocol describes reconstitution parameters used in published peptide-handling literature. It is not a recommendation for any particular study design. For research use only. Not for human consumption.
References
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91:799–805. PMID: 16352683
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139:552–561. PMID: 9849822
Was this helpful?
We reply to every research inquiry.